Suzanne Klein is the new Tisch Cancer Center Executive Director at Mount Sinai Health System and will report directly to Senior Vice President and Chief Development Officer Mark Kostegan, FAHP.
Suzanne will be principally responsible for directing the cancer-centered fundraising programs with special emphasis on pipeline development and major donor cultivation and solicitation. She will provide instrumental leadership in planning, implementing, and evaluating philanthropic initiatives for the Tisch Cancer Institute, building relationships with physician-scientists whose work focuses on TCI expertise in hematological malignancies, cancer immunotherapies and genomics. Additionally, she will hold a leadership role in raising funds for the capital campaign. Externally, Suzanne Klein will also serve as the face of Mt. Sinai’s cancer research and science focus, representing Mount Sinai to multiple constituencies.
Suzanne brings more than 25 years of development experience from healthcare, higher education and academic medical institutions, with an unusually deep focus on cancer research fundraising. Suzanne is recognized as one of the top fundraisers in the country for St. Jude Children’s Research Hospital, where she previously worked as a successful Senior Philanthropic Advisor and Director of Major Gifts. She also worked at Memorial Sloan Kettering Cancer Center in both Major and Planned Giving.
The mission of the Mount Sinai Health System is to provide compassionate patient care with seamless coordination and to advance medicine through unrivaled education, research, and outreach across its many diverse communities. In accomplishing this complex and challenging mission, the Mount Sinai Health System occupies a near-unique position in the U.S.: the only health care system anchored by a single, top-tier medical school. This creates an extraordinary setting for patients, who can take advantage of outstanding research and clinical care powered by doctors who are drawn to precisely such a setting for their work. Established in 2008, the Tisch Cancer Institute (TCI) is a vital component of the Icahn School of Medicine at Mount Sinai, renowned for its outstanding research and clinical care.